Shareholder Update October 2015
Released
Released
Announcement PDF
CONFERENCES
PARTNER NEWS
OCTOBER 2015
›› EU marketing
TECHNOLOGY
approval
granted for
VivaGel® BV
›› Multi-product
CONFERENCES
®
DEP license with
AstraZeneca
Starpharma recently achieved the
important milestone of marketing
approval in the European Union (EU) for
VivaGel® BV as a stand-alone gel for
APPOINTMENT
the topical treatment and rapid relief
of bacterial vaginosis (BV) including
symptoms.
The current market for the
management of BV and associated
symptoms is estimated to be in
excess of US$750 million globally,
with significant areas of unmet need
for BV sufferers.
The EU approval allows VivaGel®
BV to be marketed in the European
Economic Area (EEA), which includes
the 28 countries of the EU plus the
European Free Trade Association
(EFTA) countries, providing access to
a population of more than 260 million
women. The approval is also being
used to support regulatory and
marketing approvals for VivaGel® BV in
a number of other countries that
recognise the EU approval, and these
activities are now underway.
Negotiations regarding marketing
rights for VivaGel® BV are well advanced
with a number of potential commercial
partners and have been further
accelerated by the EU approval. These
commercial discussions involve partners
with extensive experience in women’s
health, and cover Western and Eastern
Europe, Asia Pacific, Latin America,
Canada and the Middle East.
In September, Starpharma signed an
important multi-product licensing
NEWS pharmaceutical
agreement PARTNER
with global
giant, AstraZeneca, for the development
of DEP® enhanced drugs from a defined
family of targets.
Key terms of the deal are:
“The EU marketing approval opens up
a very important and large market for
Starpharma in the treatment of
bacterial vaginosis – a condition with
a significant unmet medical need. The
approval will also help expedite other
approvals for the product in countries
which recognise the EU approval,
further expanding Starpharma’s
market reach.”
CEO Jackie Fairley.
› M
ilestones for the first AstraZeneca
DEP® product of USD$126 million,
and US$93 million for each
subsequent DEP® product
TECHNOLOGY
› In addition,
all AstraZeneca
DEP® products attract tiered
royalties on net sales
› A
straZeneca to fund all develop-
ment and commercialisation costs
› S
tarpharma’s DEP® platform
remainsAPPOINTMENT
unencumbered and
available for licensing in the vast
majority of oncology and other
applications
“The AstraZeneca
for future deals.
agreement clearly illustrates
the commercial potential of
Starpharma's DEP® platform.
We estimate that each qualifying
product could be worth around
US$450 million to Starpharma over
its life, and depending on the range
of indications and degree of
commercial success in the market,
potentially significantly more.”
CEO Jackie Fairley.
In October, Starpharma
received the signature
payment of US$2
million and is eligible
to receive milestone
payments and
royalties on one or
more AstraZeneca
DEP® products as they
progress through
development and
commercialisation.
›› article continued on page 3
PARTNER NEWS
VivaGel® BV – Key Facts
Symptomatic
Prevention of
relief and
Recurrence
Treatment of BV
(PoR) of BV
Time to Resolution of Discharge
› Up to 30% of
10 suffer
women
from9BV
8
› Acute Use – daily
for 77days
Days
6
›A
pproved in EU
5
– more countries
to follow
4
›N
on 3antibiotic
treatment;
2
excellent patient
1
feedback
›G
lobal market
estimated to be
more than
US$750M
› Up toVivaGel
60% of
BV
®
sufferers have
recurrent disease
Placebo
› Longer term use
56%every
– Once
2nd day
› In phase 3
clinical trials
› No current
approved options
for PoR
› Global market
estimated to be
more than US$1B
Symptomatic Relief and
Treatment of BV
In several clinical trials, VivaGel® BV
demonstrated significant benefits over
placebo in the treatment of BV and its
symptoms when used once daily for
seven days. A key benefit of VivaGel®
BV was the rapid relief of patients’
symptoms associated with BV, including
unpleasant vaginal odour and discharge.
In addition to resolution of these
®
®
®
3
2
2
1
1
-
-
›› VivaGel® condom
The VivaGel® condom has now been
rolled out to Australian pharmacies
nationally, including Chemist Warehouse,
and a number of online outlets, following
the official Australian launch of the
condom last year under Ansell’s
LifeStyles® Dual ProtectTM brand.
Regulatory processes are well
advanced in a number of other markets
and Starpharma expects that the
VivaGel® condom will be approved and
launched into a number of additional
markets over the coming year. In Japan,
Okamoto and Starpharma continue to
®
Days
APPOINTMENT
Days
Bacterial vaginosis (BV) is the most
common vaginal infection worldwide. It is
the most common cause of abnormal
vaginal discharge and unpleasant vaginal
odour in women. Up to 60% of BV
sufferers have recurrent disease.
Days
®
›› VivaGel
BV
TECHNOLOGY
Prevention of recurrence of BV
problematic symptoms, VivaGel® BV
helped to normalise vaginal pH and
The VivaGel® phase 3 clinical trial
programme for the prevention
suppress the bacteria that cause the
of recurrent BV continues to
vaginal microflora imbalance
progress smoothly with
associated with BV. Feedback
over 100 sites actively
in formal market research
“It was like gone
almost overnight”
recruiting patients and
from trial participants
recruitment now well
using VivaGel® BV was
“I would definitely
also extremely positive.
in excess of 50%.
use it again.”
BV sufferers using
The two double“The next day I noticed
VivaGel® BV reported
blind, placebo
a huge difference.”
very high levels of
controlled, trials are
“I would use it….I will use
overall satisfaction and
being conducted
it indefinitely…”
ease of use.
across North America,
VivaGel BV
Europe
and Asia. The
Trial Participants
programme is being
Time to Resolution of Odour
conducted in accordance
Placebo
VivaGel
8
with a US FDA Special Protocol
Assessment (SPA), a binding
7
agreement with the regulator that
6
significantly reduces regulatory risk
86%
through an agreed trial design. There
5
has also been agreement on the trial
4
design by the European regulatory
authority.
3
In October, Starpharma was
2
granted an additional patent for
VivaGel® BV by the US Patent Office,
1
providing a 7 year extension of the
patent term to 2032. Further patent
extension may also be available subject
Resolution of Odour
Time to Resolution of Discharge
toTime
the to
timing
of regulatory approval.
Starpharma
Chief Executive,
Dr
Placebo
VivaGel
Placebo
VivaGel
8
10
Jackie Fairley, commented: “The grant
9
7 new patent is confirmation of the
of this
8
innovation
that VivaGel® brings to the
6
56%
86%The patent is
bacterial
vaginosis
field.
7
5of several in the VivaGel® portfolio
one
6
and 4further enhances the commercial
5
value of VivaGel® BV to both partners
4
and 3shareholders.”
work closely with the regulatory
authorities to reconfirm the classification
of the VivaGel® condom to facilitate
launch.
Starpharma has also recently
received expressions of interest for the
supply of VivaGel® condoms into the
Chinese Government market and is
currently in discussions with the relevant
parties in relation to this significant
commercial opportunity. The Chinese
Government currently supplies condoms
to its citizens, with that market currently
estimated at 3 billion condoms per year.
Update
Shareholder
›› Multi-product
CONFERENCES
DEP® license with
AstraZeneca
›› Phase
1 DEP®
CONFERENCES
docetaxel trial update
In the phase 1 study of Starpharma's
DEP® docetaxel, a number of patients
For the initial DEP® product, which is an
have now been dosed at the 105mg/m2
oncology compound,
development
and
dose level with
no NEWS
cases of neutropenia
PARTNER NEWS
PARTNER
launch milestone payments of up to
(Taxotere®’s dose limiting toxicity) or
US$64 million, and sales milestone
alopecia reported. In contrast, 75% of
payments of up to an additional US$60
patients treated with the most commonly
million (total US$124 million) plus royalties used dose for Taxotere® of 75mg/m2
payable on net sales. Milestones of up
would typically experience severe
to US$93 million plus royalties will be
neutropenia.
payable on each subsequent DEP®
DEP® docetaxel has been generally
product.
well tolerated and despite the fact that
this is a phase 1 trial where enrolled
TECHNOLOGY
TECHNOLOGY
patients are expected to be less
“We already have
responsive (due to prior treatments and
a long-standing and
advanced disease), encouragingly, a
successful working
relationship with Starpharma.
significant proportion of patients treated
This license agreement will
with DEP® docetaxel have shown
enable us to further harness
potential efficacy signals in a range of
the DEP® technology…’’
tumors including
some which docetaxel
APPOINTMENT
APPOINTMENT
Susan Galbraith, Head of the
would not normally be expected to be
Oncology Innovative Medicines Unit,
effective in.
›› article continued from page 1
AstraZeneca
AstraZeneca will fund all development
and commercialisation costs under the
agreement, including ongoing and future
collaborative work conducted by
Starpharma.
The licensing deal follows a successful
collaboration with AstraZeneca, through
which Starpharma’s DEP® drug delivery
technology was applied to an important
AstraZeneca oncology candidate, with
very positive results.
›› Starpharma features
in Wall Street Journal
The Wall Street Journal reported on
Starpharma’s unique technology in both
print and video media.
“Melbourne-based Starpharma is using
nanotechnology to create a unique way
of delivering cancer drugs without side
effects such as hair loss, nausea and
bone-marrow damage.” Wall Street Journal,
5 Things to know about Australia’s Biotech Push,
15 September 2015.
The video is available at: http://www.wsj.
com/video/start-ups-driving-australiailicon-valley/3F0BF953-6679-4E6C8644-28127E68303F.html
In 2012, there were an estimated
14.1 million cases of cancer worldwide
(expected to increase to 24 million
by 2035).
›› AstraZeneca
CONFERENCES
license FAQs:
Q Is there any impact on the DEP®
docetaxel program?
PARTNER NEWS
A
Starpharma’s
other programs,
including the company’s whollyowned DEP® docetaxel product,
are not negatively impacted by this
arrangement.
Q Is there any impact on the DEP®
platform?
TECHNOLOGY
A Starpharma
retains all rights
outside of a well-defined and
narrow area of application which
means the DEP® platform remains
unencumbered and available for
licensing in the vast majority of
oncology and other applications
APPOINTMENT
for future
deals with other
partners.
Q Is this agreement only for oncology
products?
A
The compounds covered by the
agreement are for a defined family
of targets, which are not limited to
oncology. However, the first
compound is an oncology product.
› Docetaxel is indicated for use in
breast, lung, prostate, gastric, ovarian
and head and neck cancers
› These cancers accounted for almost
50% of all new cancer diagnoses
in 2012
› These cancers also represent 5 of the
top 10 most common cancers
worldwide
› In 2010, peak sales of docetaxel were in
excess of US$3 billion
Source: World Cancer Research Fund International; Medtrack
Further dose expansion and optimisation
is now underway to determine the
recommended dose for phase 2. In
parallel Starpharma is in active
discussions with key opinion leaders
locally and internationally to finalise the
design and conduct of the phase 2
program. In the context of future clinical
programs it has been identified that
DEP® docetaxel’s lack of bone marrow
toxicity (neutropenia) may make it an
ideal combination agent for
immunotherapies and this is potentially
also being explored further with
various parties.
Q
ow many products is the
H
agreement for?
A
The agreement covers any number
of products within the defined
family of targets. Each product
attracts significant additional
development and
commercialisation milestones,
as well as royalties.
Q Who will fund development and
commercialisation of these
compounds and products?
A All development and
commercialisation costs of the
DEP® compounds and products
under the agreement will be fully
funded by AstraZeneca, including
ongoing and future collaborative
work conducted with Starpharma.
Update
Shareholder
CONFERENCES
›› Agrochemicals
In recent months a number of new
agreementsCONFERENCES
have been signed or
extended with major agrochemical
companies for the European, Asian and
North American markets. Most recently,
a Priostar® collaboration was signed with
a major Japanese agrochemical
NEWS
company. InPARTNER
addition,
licence
negotiations are underway for rights
to Priostar® to enhance a number of
existing agrochemical products.
Recent regulatory compliant field
trials on Priostar® enhanced versions of
several major herbicide and fungicide
formulations showed commercially
compelling product benefits, including
improved effectiveness
and faster onset
TECHNOLOGY
of action. In addition, Starpharma has
recently developed more environmentally
friendly formulations of major herbicides
and insecticides using Priostar®
technology, which are now the subject
of commercial discussions.
APPOINTMENT
Priostar® benefits for innovative
crop protection formulations
Better in the can:
Better in the field:
› Solubility
› Increased efficacy
enhancement
› Increased loading
› Formulation
stability
› Modification of
soil penetration
› Protection of
Actives
› Reduction/removal
of solvents
– “greener”
formulations
Starpharma's Patented Priostar® offers...
Improved formulations with high
barrier to entry for competitors,
with or without new actives
›› Starpharma in
the News
›› Starpharma
full-year
PARTNER NEWS
financial results
Starpharma has attracted substantial
media coverage recently, with a large
number of top-tier articles and interviews
on various aspects of the company,
including the recent AstraZeneca license
agreementCONFERENCES
and EU approval of
VivaGel® BV.
The announcement of the
AstraZeneca deal in September
generated more than 40 pieces of media
coverage, including The Australian
PARTNER The
NEWSAustralian and the
Financial Review,
Herald Sun. CEO Jackie Fairley was also
interviewed on Sky Business News and
ABC’s The Business.
In August, Starpharma released its
annual report and financial results for the
year ended 30 June 2015. Key financial
results are summarised in the table
below.
http://www.theage.com.au/business/
starpharma-signs-deal-withastrazeneca-on-drug-deliverytechnology-20150906-gjgigy
Herald Sun columnist John
TECHNOLOGY
Beveridge noted that the beauty of
Starpharma’s DEP® technology was that
“it is exceptionally good at making all
sorts of medicines dissolve and that the
deal highlighted it “could literally be
worth $1 billion or much more as a
range of Astra
Zeneca's cancer drugs
APPOINTMENT
are switched into dramatically improved
versions.”
In June, The Australian Financial
Review also wrote a feature piece on
high-net worth investors James Dack
and Mark Carnegie joining the
Starpharma register, while The Australian
published an interview with CEO Jackie
Fairley in which she called for changes to
Australia’s superannuation system to
boost Australia’s knowledge economy
and investment in innovation.
http://www.afr.com/business/health/
biotechnology/big-hitters-mark-carnegieand-james-dack-back-aussie-biotechstarpharma-20150616-ghpa1s
TECHNOLOGY
Key Financial
Results
AUD
for financial
year 2015
Total revenue and other
income
$1.7M
R&D tax incentive
$3.5M
Net loss after
tax
APPOINTMENT
($19.0M)
Operating and investing
cash outflows
($14.3M)
Cash at 30 June 2015
$30.8M
CONFERENCES
›› Presentations and
conferences
In addition to a number of industry and
PARTNER NEWS
investor conferences,
Starpharma’s CEO
Jackie Fairley recently presented at the
OTCQX Life Sciences Virtual Investor
conference which attracted over 500
investors. Dr Fairley gave an introduction
to the company and an update on the
AstraZeneca licensing deal and EU
marketing approval for VivaGel® BV.
The presentation is available for
viewing at TECHNOLOGY
http://www.
virtualinvestorconferences.com/
agenda-oct2015.html
Starpharma Holdings Limited Company
(ASX:SPL; OTCQX:SPHRY)
Nigel Baade
ABN 20 078 532 180
CFO/Company Secretary
4-6 Southampton Crescent
+61 3 8532 2704
Abbotsford
investor.relations@
APPOINTMENT starpharma.com
Vic 3067
+61 3 8532 2700
www.starpharma.com
Media Relations
Rebecca Wilson
Buchan Consulting
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”,
“forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions
regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’
requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.
In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical
data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government,
industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the
date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
Share your feedback
Discover